Skip to main content
. 2013 Sep 3;31(28):3525–3530. doi: 10.1200/JCO.2013.50.1684

Fig 3.

Fig 3.

Steady-state ARN-509 plasma trough concentrations in patients and in murine model of castration-resistant prostate cancer (CRPC). Mean predose ARN-509 concentrations for patients in each dose cohort (error bars indicate standard deviation) and steady-state trough concentrations associated with efficacy in clinically validated LNCaP/androgen receptor model of CRPC.